title: A short update on cancer chemoresistance.
abstract: Chemotherapeutic interventions in cancer patients are limited by the appearance of chemoresistance. For instance, advanced lung and ovarian cancer patients relapse invariably after few cycles of platinum-based chemotherapy. Disseminated tumors are characterized by genetic instability/heterogeneity, thus containing or generating a repertoire of resistant subpopulations. At the cellular level, altered drug uptake, efflux, and metabolization, as well as modifications of drug targets, increased repair, and decreased cell death complement the limited perfusion and adverse hypoxic/acidic extracellular conditions at the tumor level in retaining cancer cell viability. Similarly, targeted therapy is rendered ineffective by mutations of the specific target protein within a few months or years of administration. Assessment of the expression profiles of resistant tumor cells revealed extensive changes in numerous pathways affecting hundreds of genes. Therefore, reversal of drug resistance will require individual profiles of drug resistance mediators and the combination of several specific drugs, targeting critical components to provide new therapeutic options.
authors.affiliation: Ludwig Boltzmann Cluster of Translational Oncology, c/o Balderichgasse 26/13, 11170, Vienna, Austria, gerhard.hamilton@toc.lbg.ac.at.
authors.forename: Gerhard
authors.initials: G
authors.lastname: Hamilton
authors.forename: Barbara
authors.initials: B
authors.lastname: Rath
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D016031:Liver Transplantation; D035683:MicroRNAs / Q000032:analysis / Q000235:genetics; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011379:Prognosis; D000077157:Sorafenib
chemical_list: D035683:MicroRNAs; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib